Full metadata record

DC Field Value Language
dc.contributor.author이종원-
dc.contributor.author최지원-
dc.contributor.authorChoi Y.-
dc.contributor.authorKim, Kwang meyung-
dc.contributor.author양유수-
dc.contributor.author김선화-
dc.contributor.author윤홍열-
dc.contributor.author권익찬-
dc.date.accessioned2024-01-12T02:35:43Z-
dc.date.available2024-01-12T02:35:43Z-
dc.date.created2022-11-03-
dc.date.issued2022-11-
dc.identifier.issn0168-3659-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/75952-
dc.description.abstractRNA interference (RNAi) is a major cellular mechanism regulating gene expression in which short double-stranded RNA molecules called small interfering RNA (siRNA) mediate sequence-specific mRNA degradation. RNAi technology has recently emerged as a promising therapeutic platform for the effective treatment of various diseases caused by inappropriate gene activity, such as cancer. However, the clinical translation of siRNA therapeutics has been hampered by the major hurdles associated with biological instability and limited delivery efficiency. Based on the various efforts, recent siRNA delivery strategies using cationic lipids and polymers allowed to enhance pharmacokinetics and delivery efficiency, resulting in potent and liver-targeted RNAi therapy. However, non-specific protein adsorption, high liver accumulation, and severe toxicity of cationic nanocarriers still limit the possibility of transfer of siRNA therapeutics from the laboratory to the clinic. One of the promising delivery strategies to overcome the limitations of siRNA therapeutics is carrier-free bioconjugation which is chemically modified and connected with biocompatible molecules such as lipids, peptides, antibodies, aptamers, and polymers. These molecularly engineered siRNA conjugates can be utilized for RNAi delivery to tissues beyond the liver, providing opportunities for clinical translation. This review focused on introducing the recent progress in molecularly engineered siRNA conjugates and their applications toward overcoming the limitations of siRNA for tumor-targeted delivery and therapy.-
dc.languageEnglish-
dc.publisherElsevier BV-
dc.titleMolecularly engineered siRNA conjugates for tumor-targeted RNAi therapy-
dc.typeArticle-
dc.identifier.doi10.1016/j.jconrel.2022.09.040-
dc.description.journalClass1-
dc.identifier.bibliographicCitationJournal of Controlled Release, v.351, pp.713 - 726-
dc.citation.titleJournal of Controlled Release-
dc.citation.volume351-
dc.citation.startPage713-
dc.citation.endPage726-
dc.description.isOpenAccessY-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000883338700003-
dc.identifier.scopusid2-s2.0-85139311023-
dc.relation.journalWebOfScienceCategoryChemistry, Multidisciplinary-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.relation.journalResearchAreaChemistry-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeArticle-
dc.subject.keywordPlusGENE-SILENCING ACTIVITY-
dc.subject.keywordPlusSMALL INTERFERING RNA-
dc.subject.keywordPlusCO-DELIVERY-
dc.subject.keywordPlusINTRACELLULAR DELIVERY-
dc.subject.keywordPlusCHEMICAL-MODIFICATION-
dc.subject.keywordPlusIN-VIVO-
dc.subject.keywordPlusCYTOSOLIC DELIVERY-
dc.subject.keywordPlusCELLULAR UPTAKE-
dc.subject.keywordPlusVEGF SIRNA-
dc.subject.keywordPlusPEPTIDE-
dc.subject.keywordAuthorGene delivery-
dc.subject.keywordAuthorRNA interference-
dc.subject.keywordAuthorSmall interfering RNA-
dc.subject.keywordAuthorcancer therapy-
dc.subject.keywordAuthorsiRNA conjugates-
Appears in Collections:
KIST Article > 2022
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE